<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.1011391</article-id><article-id pub-id-type="publisher-id">ACM-38686</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20201100000_12439346.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  肝素诱导的血小板减少症诊治进展
  Progress in the Diagnosis of Heparin-Induced Thrombocytopenia
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>齐</surname><given-names>微</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>悦</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>哲</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>夜</surname><given-names>雪敏</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>邢</surname><given-names>延芳</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>延安大学医学院，陕西 延安</addr-line></aff><aff id="aff3"><addr-line>延安大学附属东关分院检验科，陕西 延安</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>04</day><month>11</month><year>2020</year></pub-date><volume>10</volume><issue>11</issue><fpage>2582</fpage><lpage>2587</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    肝素诱导的血小板减少症(Heparin-induced thrombocytopenia, HIT)是使用肝素抗凝治疗后出现的一种严重不良反应，可导致血栓形成，造成器官或肢体血栓栓塞，严重者危及生命。由于HIT临床过程隐匿，且症状不典型，易造成误诊和漏诊。然而，国内对HIT的认知和诊疗严重不足。本文通过检索HIT相关文献，对HIT的发病机制、临床表现、诊断及治疗作一综述，旨在为临床医生早期诊断、鉴别和治疗提供参考。
    Heparin-induced thrombocytopenia (HIT) is a common complication of heparin anticoagulant therapy, which can lead to thromboembolism in organs or limbs, and serious life-threatening. Due to the clinical process of HIT is concealed and the symptoms are not typical, it is easy to cause missed and delayed diagnosis. However, there are serious insufficiency in the cognition and diagnosis of HIT in domestic. This article intends to describe the latest developments in the clinical manifestations, laboratory tests and diagnosis, in order to guide clinicians to early identify and diagnose of the syndrome. 
  
 
</p></abstract><kwd-group><kwd>肝素，血小板减少，HIT抗体，血栓栓塞，抗凝药, Heparin</kwd><kwd> Thrombocytopenia</kwd><kwd> HIT Antibody</kwd><kwd> Thromboembolism</kwd><kwd> Anticoagulant</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>肝素诱导的血小板减少症(Heparin-induced thrombocytopenia, HIT)是使用肝素抗凝治疗后出现的一种严重不良反应，可导致血栓形成，造成器官或肢体血栓栓塞，严重者危及生命。由于HIT临床过程隐匿，且症状不典型，易造成误诊和漏诊。然而，国内对HIT的认知和诊疗严重不足。本文通过检索HIT相关文献，对HIT的发病机制、临床表现、诊断及治疗作一综述，旨在为临床医生早期诊断、鉴别和治疗提供参考。</p></sec><sec id="s2"><title>关键词</title><p>肝素，血小板减少，HIT抗体，血栓栓塞，抗凝药</p></sec><sec id="s3"><title>Progress in the Diagnosis of Heparin-Induced Thrombocytopenia<sup> </sup></title><p>Wei Qi<sup>1</sup>, Yue Wang<sup>1</sup>, Zhe Wang<sup>1</sup>, Xuemin Ye<sup>1</sup>, Yanfang Xing<sup>2*</sup></p><p><sup>1</sup>Medical College of Yan’an University, Yan’an Shaanxi</p><p><sup>2</sup>Department of Laboratory Medicine, Dongguan Branch of Yan’an University, Yan’an Shaanxi</p><p><img src="//html.hanspub.org/file/25-1571666x5_hanspub.png" /></p><p>Received: Nov. 1<sup>st</sup>, 2020; accepted: Nov. 13<sup>th</sup>, 2020; published: Nov. 20<sup>th</sup>, 2020</p><p><img src="//html.hanspub.org/file/25-1571666x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Heparin-induced thrombocytopenia (HIT) is a common complication of heparin anticoagulant therapy, which can lead to thromboembolism in organs or limbs, and serious life-threatening. Due to the clinical process of HIT is concealed and the symptoms are not typical, it is easy to cause missed and delayed diagnosis. However, there are serious insufficiency in the cognition and diagnosis of HIT in domestic. This article intends to describe the latest developments in the clinical manifestations, laboratory tests and diagnosis, in order to guide clinicians to early identify and diagnose of the syndrome.</p><p>Keywords:Heparin, Thrombocytopenia, HIT Antibody, Thromboembolism, Anticoagulant</p><disp-formula id="hanspub.38686-formula13"><graphic xlink:href="//html.hanspub.org/file/25-1571666x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/25-1571666x8_hanspub.png" /> <img src="//html.hanspub.org/file/25-1571666x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>肝素作为一种临床广泛使用的抗凝药，其所引起的不良反应逐渐引起人们的重视，其中最严重的并发症是肝素诱导的血小板减少症(Heparin-induced thrombocytopenia, HIT) [<xref ref-type="bibr" rid="hanspub.38686-ref1">1</xref>]，因此早期诊断并实施干预可以避免出现血栓栓塞等严重并发症。国外研究报道，在接受肝素治疗的患者中HIT发病率约为0.5%~5% [<xref ref-type="bibr" rid="hanspub.38686-ref2">2</xref>]。一旦发生，如果处理不及时将会造成严重后果。</p><p>既往将HIT分为两种类型，即I型HIT和II型HIT。I型是一种非免疫性疾病，一般在使用肝素治疗后的2~3天内出现血小板计数轻度下降，患者常无临床症状，并且无需停用肝素治疗，血小板计数可自行恢复正常，其机制是肝素与血小板表面αⅡbβ3受体直接作用引起血小板活化、释放，从而导致血小板一过性减少 [<xref ref-type="bibr" rid="hanspub.38686-ref3">3</xref>]。II型为免疫相关性，即本文所指的HIT。本文通过检索HIT相关文献，就HIT的发病机制、临床表现、诊断及治疗作一简要综述。</p></sec><sec id="s6"><title>2. 发病机制</title><p>生理情况下血小板因子4 (PF4)储存于血小板α颗粒中，当血小板受到刺激时，PF4释放入血，与体内带负电荷的葡胺聚糖生物分子肝素结合，使PF4构象发生改变从而暴露抗原表位，形成PF4/肝素复合物，可刺激机体产生PF4/肝素抗体(主要是IgG) [<xref ref-type="bibr" rid="hanspub.38686-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.38686-ref5">5</xref>]。该抗体的Fab片段可识别具有抗原性的PF4/肝素，并与其特异性结合，同时Fc片段与血小板表面的FcγRIIa受体结合进一步促进血小板活化与聚集，这种正反馈机制导致血小板不断减少和机体高凝状态 [<xref ref-type="bibr" rid="hanspub.38686-ref6">6</xref>]。此外，PF4/肝素抗体还可作用于单核细胞和内皮细胞，诱导组织因子释放，引起血管内皮损伤，导致血栓形成。</p></sec><sec id="s7"><title>3. 临床表现</title><p>HIT最主要的临床表现是血小板减少，通常出现在使用肝素治疗后的5~14天内，多数血小板计数降至基线值的50%以下 [<xref ref-type="bibr" rid="hanspub.38686-ref7">7</xref>]。值得注意的是，一部分患者血小板计数下降了50%，但绝对值仍在正常范围内，这就容易导致对HIT的漏诊 [<xref ref-type="bibr" rid="hanspub.38686-ref8">8</xref>]。如停用肝素后，血小板计数仍 &lt; 20 &#215; 10<sup>9</sup>/L时，应该考虑其他原因导致的血小板减少 [<xref ref-type="bibr" rid="hanspub.38686-ref9">9</xref>]，例如感染、药物等引起的血小板减少，免疫性血小板减少性紫癜，EDTA诱导的血小板聚集等。血小板计数相对减少是诊断HIT的关键，所以动态监测血小板十分必要。HIT引起的出血较少见，但其发生血栓的风险显著增高。静脉血栓是HIT最常见的并发症。研究发现静脉血栓的发生率高于动脉血栓(约为4:1)，虽然动脉血栓发生率较低，但可造成脑卒中和心肌梗塞等严重并发症 [<xref ref-type="bibr" rid="hanspub.38686-ref10">10</xref>]。HIT也会引起局部皮肤损害和急性全身反应，部分患者在肝素注射部位会出现皮肤红斑，甚至坏死 [<xref ref-type="bibr" rid="hanspub.38686-ref11">11</xref>]。全身反应包括静脉注射肝素5~30 min后出现的如发热、寒颤、心动过速、胸痛、呼吸困难等症状 [<xref ref-type="bibr" rid="hanspub.38686-ref12">12</xref>]。</p></sec><sec id="s8"><title>4. 临床诊断与实验室检查</title><sec id="s8_1"><title>4.1. 评分系统</title><p>临床诊断HIT主要依据评分系统，目前主要使用的有三种，分别为4Ts评分系统、HEP评分系统(即HIT专家意见评分系统)、CPB评分系统(即体外循环术后评分系统)。其中最常用的是4Ts评分，主要根据血小板减少的程度、与肝素暴露相关的血小板减少的时间、血栓并发症的存在及其他原因导致的血小板下降来评估发生HIT的可能性 [<xref ref-type="bibr" rid="hanspub.38686-ref13">13</xref>]。4Ts得分0至3分，4至5分和6至8分分别对应于发生HIT的低、中、高概率。4Ts评分有很高的阴性预测值(99.8%)，但特异性较低。中、高概率4Ts评分的阳性预测值分别为14%和64% [<xref ref-type="bibr" rid="hanspub.38686-ref14">14</xref>]。</p><p>HEP评分系统是基于26位HIT相关领域专家的意见，HEP评分由8个与HIT诊断相关的临床特征组成，分别是血小板计数下降幅度、血小板计数下降时间、血小板计数、血栓症、皮肤坏死、急性全身反应、出血、血小板减少的其他原因。由于HEP评分比4Ts评分相对复杂，故在临床中使用较少 [<xref ref-type="bibr" rid="hanspub.38686-ref15">15</xref>]。有研究发现，在临床经验较少的临床医生和患有严重疾病的患者中，HEP评分可能优于4Ts评分 [<xref ref-type="bibr" rid="hanspub.38686-ref16">16</xref>]。</p><p>CPB评分系统主要应用于体外循环术(CPB)后患者，通过动态监测血小板变化、体外循环术后持续时间、CPB术后到疑似HIT的时间作为判断指标。一项回顾性分析显示，CPB评分阴性预测值高达97%，但仍需要大量的前瞻性研究 [<xref ref-type="bibr" rid="hanspub.38686-ref17">17</xref>]。然而，无论使用哪种评估系统，精准判断患者的临床表现才是评估的关键。</p></sec><sec id="s8_2"><title>4.2. 实验室检测</title><p>除密切观察患者临床表现和PLT计数动态变化外，对于高度可疑的HIT患者进行进一步实验室检测很有必要。HIT的实验室检查包括血小板功能检测和HIT抗体检测。功能性检测包括血清素释放实验(SRA)和肝素诱导的血小板活化实验(HIPA)。SRA因其具有高灵敏度和特异性而被视为HIT的“金标准”，其原理是使用放射性标记来量化血清素的释放。将供体富含血小板的血浆与<sup>14</sup>C标记的血清素共同温育，被放射性标记的血清素进入血小板致密颗粒，然后洗涤血小板除去过量的<sup>14</sup>C-血清素，将洗过的血小板与患者血清/血浆和肝素一起孵育，离心后测试上清液的放射量 [<xref ref-type="bibr" rid="hanspub.38686-ref18">18</xref>]。然而，该测定方法耗时、昂贵且具有放射性，很少有实验室能够进行。</p><p>HIT抗体检测包括酶联免疫分析测定(ELISA)、全自动乳胶免疫比浊法(LIA)、化学发光免疫学分析法(CLIA)等。酶联免疫分析试验是目前实验室最常用的的免疫检测方法，也是目前较为公认的HIT筛查方法，该方法操作简单且容易确定统一标准，目前在临床上应用广泛。但研究发现ELISA检测阳性的患者并不一定发生HIT，周硕福等通过检测315例心脏手术患者围术期的PLT、PF4、HIT，发现HIT抗体阳性率为36.5%，而HIT发生率仅有3.5% [<xref ref-type="bibr" rid="hanspub.38686-ref19">19</xref>]。所以临床仅依据抗体检测结果将会导致HIT的过度诊断，还需与评分系统联合应用以排除HIT。</p></sec><sec id="s8_3"><title>4.3. HIT的诊断</title><p>目前诊断HIT主要依靠临床评估和实验室检查。对所有使用肝素治疗的患者应动态监测血小板，尤其是近3个月内有肝素使用史的患者，如果出现血小板减少或急性血栓形成更应该警惕HIT发生，对于高度疑似患者可行4Ts评估。2018年肝素诱导的血小板减少症中国专家共识建议将4Ts评分作为诊断HIT的初步筛查试验 [<xref ref-type="bibr" rid="hanspub.38686-ref20">20</xref>]。4Ts评分有很高的阴性预测值，所以低概率临床评估患者可排除HIT，对于中、高概率临床评估患者，需检测HIT抗体。诊断HIT时应排除其他能引起血小板减少的因素。</p></sec></sec><sec id="s9"><title>5. HIT的治疗现状</title><sec id="s9_1"><title>5.1. 立即停用肝素</title><p>对于临床诊断和高度疑似HIT患者应立即停止使用肝素，包括使用肝素、低分子肝素，并给以非肝素抗凝剂替代治疗 [<xref ref-type="bibr" rid="hanspub.38686-ref21">21</xref>]。尽管HIT患者血小板计数较低，但其出血风险小，应避免预防输注血小板，否则会加重血栓形成的风险 [<xref ref-type="bibr" rid="hanspub.38686-ref22">22</xref>]。</p></sec><sec id="s9_2"><title>5.2. 替代抗凝</title><p>目前临床常使用的替代抗凝药有阿加曲班、比伐卢定、磺达肝癸钠。阿加曲班、比伐卢定为直接凝血酶抑制剂，可以快速结合凝血酶的活性中心，阻止纤维蛋白的形成而达到抗凝作用 [<xref ref-type="bibr" rid="hanspub.38686-ref23">23</xref>]。阿加曲班被美国食品药品监督管理局(FDA)批准用于治疗HIT及在禁忌肝素时进行经皮冠状动脉(PCI)治疗的患者的抗凝作用 [<xref ref-type="bibr" rid="hanspub.38686-ref24">24</xref>]，其半衰期为40~50 min，主要通过肝脏代谢，可用于肾功能不全的患者 [<xref ref-type="bibr" rid="hanspub.38686-ref25">25</xref>]。比伐卢定是一种水蛭素类似物，20%经肾脏排泄，其药物代谢动力学特性也不受年龄和性别的影响 [<xref ref-type="bibr" rid="hanspub.38686-ref26">26</xref>]。晋辉等通过对94例HIT-IgG抗体阳性的STEMI患者PCI术后抗凝效果的观察，发现比伐卢定和阿加曲班的抗凝效果相当 [<xref ref-type="bibr" rid="hanspub.38686-ref27">27</xref>]。</p><p>磺达肝癸钠是一种合成的肝素分子类似物，通过抑制凝血因子Xa而发挥抗凝作用。有研究报道磺达肝癸钠用于高度疑似HIT患者的抗凝治疗是安全有效的 [<xref ref-type="bibr" rid="hanspub.38686-ref28">28</xref>]。然而也有病例报道发现磺达肝癸钠与抗血小板因子4抗体发生交叉反应，导致血小板持续降低，引起弥散性血管内凝血 [<xref ref-type="bibr" rid="hanspub.38686-ref29">29</xref>]。</p><p>近年来出现了一些新型口服抗凝剂(达比加群、利伐沙班、阿哌沙班)，但目前对该类药物治疗HIT的研究主要还是来自体外实验，仍需大量临床研究加以验证。尽管对于HIT的治疗主要是强调使用非肝素抗凝药物，但有研究发现可将大剂量静脉注射免疫球蛋白(intravenous immune globulin, IVIG)用于治疗严重或持续性的HIT [<xref ref-type="bibr" rid="hanspub.38686-ref30">30</xref>]。一项系统性回顾研究分析了有关使用IVIG治疗的34例HIT患者，发现使用IVIG后约77%的患者病情好转，且Logistic回归未发现任何预测IVIG不良反应的因素，因此IVIG对于HIT和难治性血栓形成似乎是一种安全有效的治疗选择 [<xref ref-type="bibr" rid="hanspub.38686-ref31">31</xref>]。</p></sec></sec><sec id="s10"><title>6. 结语</title><p>HIT是在使用肝素治疗过程中出现的严重威胁生命的并发症，具有极高的致残率和致死率。目前血小板活化试验阳性或HIT抗体强阳性是诊断HIT的有力证据。但血小板活化试验难以开展，HIT抗体检测不具有特异性，所以HIT诊断仍是一个具有挑战的临床问题。相信随着实验室检测技术的不断发展，会有一种高特异性和灵敏度的检测方法，能有效的区分致病性和非致病性抗体。在此之前，仍需要临床医师加强对HIT的认识，积累丰富的临床经验，随着对该疾病的深入了解，HIT的诊治会更加规范化。</p></sec><sec id="s11"><title>文章引用</title><p>齐 微,王 悦,王 哲,夜雪敏,邢延芳. 肝素诱导的血小板减少症诊治进展Progress in the Diagnosis of Heparin-Induced Thrombocytopenia[J]. 临床医学进展, 2020, 10(11): 2582-2587. https://doi.org/10.12677/ACM.2020.1011391</p></sec><sec id="s12"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.38686-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">武东, 汪晓娟, 汪小五, 等. 104例住院患者药源性血小板减少症不良反应报告分析[J]. 中国医院药学杂志, 2019, 39(17): 1766-1771.</mixed-citation></ref><ref id="hanspub.38686-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Warkentin, T.E., Sheppard, J.A., Horsewood, P., et al. (2000) Impact of the Patient Population on the Risk for Heparin-induced Thrombocytopenia. Blood, 96, 1703-1708.  
&lt;br&gt;https://doi.org/10.1182/blood.V96.5.1703.h8001703_1703_1708</mixed-citation></ref><ref id="hanspub.38686-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Shen, Y.-M., Heather, W. and Stephen, B. (2018) Evaluating Thrombocytopenia during Heparin Therapy. JAMA, 319, 497. &lt;br&gt;https://doi.org/10.1001/jama.2017.21898</mixed-citation></ref><ref id="hanspub.38686-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">郑永威, 袁榴娣. 肝素诱导性血小板减少症的研究进展[J]. 东南大学学报(医学版), 2014, 33(6): 815-819.</mixed-citation></ref><ref id="hanspub.38686-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">雷迁, 陈雷. 肝素/血小板因子4抗体与肝素诱导的血小板减少症[J]. 中国实验血液学杂志, 2008(2): 457-460.</mixed-citation></ref><ref id="hanspub.38686-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Rauova, L., Arepally, G., Poncz, M., et al. (2018) Molecular and Cellular Pathogenesis of Heparin-Induced Thrombocytopenia (HIT). Autoimmunity Reviews, 17, 1046-1052. &lt;br&gt;https://doi.org/10.1016/j.autrev.2018.05.003</mixed-citation></ref><ref id="hanspub.38686-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">曹磊, 谭颖, 吕继成, 等. 肝素诱导的血小板减少症[J]. 中国血液净化, 2009, 8(3): 163-166.</mixed-citation></ref><ref id="hanspub.38686-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">范庆坤, 张真路. 如何面对肝素诱导血小板减少症诊断的困惑[J]. 中华检验医学杂志, 2019, 42(4): 227-231.</mixed-citation></ref><ref id="hanspub.38686-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">门剑龙, 任静. 肝素诱导的血小板减少症的实验室诊断进展[J]. 中华检验医学杂志, 2016, 39(10): 795-800.</mixed-citation></ref><ref id="hanspub.38686-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Warkentin, T.E. (2012) HITlights: A Career Perspective on Heparin-Induced Thrombocytopenia. American Journal of Hematology, 87, S92-S99. &lt;br&gt;https://doi.org/10.1002/ajh.23127</mixed-citation></ref><ref id="hanspub.38686-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Cohen, R.A., Castellano, M. and Garcia, C.A. (2012) Heparin Induced Thrombocytopenia: Case Presentation and Review. Journal of Clinical Medicine Research, 4, 68-72. &lt;br&gt;https://doi.org/10.4021/jocmr751w</mixed-citation></ref><ref id="hanspub.38686-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Dasararaju, R., Singh, N. and Mehta, A. (2013) Heparin Induced Thrombocytopenia: Review. Expert Review of Hematology, 6, 419-428. &lt;br&gt;https://doi.org/10.1586/17474086.2013.814446</mixed-citation></ref><ref id="hanspub.38686-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Cuker, A., Rux, A.H., Hinds, J.L., et al. (2013) Novel Diagnostic Assays for Heparin-Induced Thrombocytopenia. Blood, 121, 3727-3732. &lt;br&gt;https://doi.org/10.1182/blood-2013-01-479576</mixed-citation></ref><ref id="hanspub.38686-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Cuker, A., Gimotty, P.A., Crowther, M.A., et al. (2012) Predictive Value of the 4Ts Scoring System for Heparin-Induced Thrombocytopenia: A Systematic Review and Meta-Analysis. Blood, 120, 4160-4167.  
&lt;br&gt;https://doi.org/10.1182/blood-2012-07-443051</mixed-citation></ref><ref id="hanspub.38686-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Joseph, L., Gomes, M.P.V., Al, S.F., et al. (2015) External Validation of the HIT Expert Probability (HEP) Score. Thrombosis and Haemostasis, 113, 633-640. &lt;br&gt;https://doi.org/10.1160/TH14-05-0472</mixed-citation></ref><ref id="hanspub.38686-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Pishko, A.M., Fardin, S., Lefler, D.S., et al. (2018) Prospective Comparison of the Hep Score and 4ts Score for the Diagnosis of Heparin-Induced Thrombocytopenia. Blood Advances, 2, 3155-3162.  
&lt;br&gt;https://doi.org/10.1182/bloodadvances.2018023077</mixed-citation></ref><ref id="hanspub.38686-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Lillo-Le, L.A., Boutouyrie, P., Alhenc-Gelas, M., et al. (2004) Diagnostic Score for Heparin-Induced Thrombocytopenia after Cardiopulmonary Bypass. Journal of Thrombosis and Haemostasis, 2, 1882-1888.  
&lt;br&gt;https://doi.org/10.1111/j.1538-7836.2004.00949.x</mixed-citation></ref><ref id="hanspub.38686-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Compton, F.B., Alrabeh, R., Nguyen, L.Q., et al. (2018) Pifa Pluss P4 Assay for Screening of Heparin-Induced Throm- bocytopenia. Laboratory Medicine, 50, 73-77. &lt;br&gt;https://doi.org/10.1093/labmed/lmy048</mixed-citation></ref><ref id="hanspub.38686-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">周福硕, 黄凌瑾, 王锷, 等. 心脏手术患者围术期肝素诱导的血小板减少症[J]. 中南大学学报(医学版), 2015, 40(7): 790-796.</mixed-citation></ref><ref id="hanspub.38686-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">中国医师协会心血管内科医师分会血栓防治专业委员会与编辑委员会. 肝素诱导的血小板减少症中国专家共识(2017) [J]. 中华医学杂志, 2018, 98(6): 408-417.</mixed-citation></ref><ref id="hanspub.38686-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">于坤, 梁碧霞, 刘明政, 等. 肝素诱导的血小板减少症患者心脏外科手术期间抗凝治疗[J]. 中国体外循环杂志, 2018, 16(5): 297-301.</mixed-citation></ref><ref id="hanspub.38686-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">张明哲, 姚允泰, 李立环. 心脏手术患者肝素诱导血小板减少症[J]. 中国体外循环杂志, 2018, 16(5): 293-296, 311.</mixed-citation></ref><ref id="hanspub.38686-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">冯湧. 新一代抗凝血药阿加曲班的临床应用进展[J]. 医学信息, 2018, 31(2): 43-45.</mixed-citation></ref><ref id="hanspub.38686-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Nutescu, E.A., Shapiro, N.L. and Chevalier, A. (2007) New Anticoagulant Agents: Direct Thrombin Inhibitors. Cardiology Clinics, 26, 169-187. &lt;br&gt;https://doi.org/10.1016/j.ccl.2007.12.005</mixed-citation></ref><ref id="hanspub.38686-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Zhou, P., Yin, J.-X., Tao, H.-L., et al. (2020) Pathogenesis and Management of Heparin-Induced Thrombocytopenia and Thrombosis. Clinica Chimica Acta, 504, 73-80. &lt;br&gt;https://doi.org/10.1016/j.cca.2020.02.002</mixed-citation></ref><ref id="hanspub.38686-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">伍雪峰, 金至赓, 赖斌, 刘惠亮. 急性冠脉综合征患者经皮冠状动脉介入术中比伐卢定的研究进展[J]. 中华灾害救援医学, 2017, 5(2): 101-105.</mixed-citation></ref><ref id="hanspub.38686-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">晋辉, 邱翠婷, 刘静, 等. 比较阿加曲班和比伐卢定在高出血风险且肝素诱导的血小板减少症-IgG抗体阳性的ST段抬高型心肌梗死患者急诊经皮冠状动脉介入治疗中的抗凝疗效[J]. 中国循环杂志, 2019, 34(6): 545-551.</mixed-citation></ref><ref id="hanspub.38686-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Marc, S., Julia, S., Jan, B.-W., et al. (2017) Use of Fondaparinux Off-Label or Approved Anticoagulants for Management of Heparin-Induced Thrombocytopenia. Journal of the American College of Cardiology, 70, 2636-2648.  
&lt;br&gt;https://doi.org/10.1016/j.jacc.2017.09.1099</mixed-citation></ref><ref id="hanspub.38686-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Poudel, Ghimire, Dhital, et al. (2017) Spontaneous Hit Syndrome Post-Knee Replacement Surgery with Delayed Recovery of Thrombocytopenia: A Case Report and Literature Review. Platelets, 28, 614-620.  
&lt;br&gt;https://doi.org/10.1080/09537104.2017.1366973</mixed-citation></ref><ref id="hanspub.38686-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Tvito, A., Bakchoul, T., Rowe, J.M., et al. (2015) Severe and Persistent Heparin-Induced Thrombocytopenia Despite Fondaparinux Treatment. American Journal of Hematology, 90, 675-678. &lt;br&gt;https://doi.org/10.1002/ajh.23971</mixed-citation></ref><ref id="hanspub.38686-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Aryal, M.R., Gosain, R., Donato, A., et al. (2020) Effectiveness of Intravenous Immunoglobulin Use in Heparin-Induced Thrombocytopenia. Blood Coagulation &amp; Fibrinolysis, 31, 287-292. &lt;br&gt;https://doi.org/10.1097/MBC.0000000000000918</mixed-citation></ref></ref-list></back></article>